WellMarker Bio greatly accelerates the development of predictive biomarker-based anticancer drug

Dr. Dong-Hoon Jin, Founder and CEO of WellMarker Bio Co., Ltd (WMBIO), speaks at BIO-Europe 2019 in Hamburg about their several programs focused on the predictive biomarker based anticancer drugs to identity novel targets. WMBIO is a spin-off company from Seoul Asan Medical Center, which is the biggest and most renowned hospital in the Republic of Korea. The company specializes in discovering and defining novel predictive biomarkers and utilizes these to develop ideal matching drug candidates. As a result, WMBIO can shorten the lead time, reduce the development cost, and increase the success rate in first-in-class anti-cancer drugs.

Dong Hoon Jin,Wellmarker Bio,WMBIO,BIO-Europe,pharma,biotech,partnering,drug development,drug discovery,EBD Group,